⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for 160 mg regorafenib at week 3

Every month we try and update this database with for 160 mg regorafenib at week 3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal CancerNCT05730673
CCR5
Microsatellite ...
Metastatic
Colorectal Canc...
700mg leronlima...
80mg Regorafeni...
120mg Regorafen...
160 mg Regorafe...
18 Years - CytoDyn, Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: